Black Diamond Therapeutics, Inc. — Director's Dealing 2021

Jun 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-06-18

Reporting Person: Bolzon Bradley J PhD (Director, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-18	Stock Option (Right to Buy)	$12.55	A	15000	Acquired	2031-06-17	Common Stock (15000)	Direct

Footnotes

F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.